Amgen Inc.’s third-quarter profit beat Wall Street estimates as the company’s expenses were lower than anticipated.

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Shares of Eli Lilly and Co. slumped toward their biggest selloff in more than three years on Wednesday, after the drugmaker reported third-quarter results that missed expectations, due to big misses ...

The Danish transport company sold a six-part bond deal with maturities ranging from two to 10 years, according to a person familiar with the matter.

Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's website on ...

Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.